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Abstract. In this paper, the synthesis and characterization of some imidazole-based gold-selenolates are
described. This study indicates that the nature of selenolate plays an important role in ligand exchange reactions
in gold(I) selenolates. Furthermore, the reactivity of imidazole-based gold(I) selenolates toward nucleophiles
such as selenols and phosphines is strikingly different from that of the N,N-dimethylaminobenzylamine-based
gold(I) complexes. The presence of Se· · · N non-bonded interactions in N,N-dimethylaminobenzylamine-based
gold(I) complexes modulates the reactivity of Au(I) centre towards incoming nucleophiles.
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1. Introduction
Gold(I) complexes such as auranofin (1, AUR), gold
thioglucose (2, GTG) and gold thiomalate (3, GTM)
(figure 1) have been used as therapeutic drugs for
Rheumatoid Arthritis (RA) for a long period of time.1
The biochemical mechanism for the action of these
compounds in RA is complex as these compounds inter-
act with several biomolecules. Owing to the higher
affinity of gold(I) towards sulfur and selenium, gold(I)
drugs rapidly react with activated cysteine or seleno-
cysteine residues of enzymes to form protein-gold(I)-
thiolate or protein-gold(I)-selenolate complexes.2 It is
known that the gold(I) drugs rapidly bind to the most
abundant plasma protein serum albumin (Alb-SH) after
their administration, which is important for the trans-
port of these drugs.3 The interaction of AUR with Alb-
SH has been studied extensively in recent years and
these studies reveal that AUR reacts with the active
site cysteine residue (Cys-34) of Alb-SH to produce
the corresponding albumin-gold(I)-phosphine (Alb-S-
Au-PEt3) complex.3
Similarly, the gold–phosphole complex 4 has been
shown to react with the Cys-284 of human glutathione
reductase (hGR) to produce a stable protein-gold(I)-
phosphole (Cys284-S-Au-phosphole) complex.4 Inter-
estingly, gold(I) drugs effectively inhibit several seleno-
∗For correspondence
enzymes such as glutathione peroxidase (GPx),5 thiore-
doxin reductase (TrxR)6 and iodothyronine deiodinase
(ID-1),7 by forming gold(I)–selenolate complexes with
the selenocysteine (Sec) residues at the active sites. The
formation of gold(I)–selenolate complexes in proteins
appears to be more facile than the formation of gold(I)–
thiolates. For example, the substitution of Sec in ID-1
by a Cys residue significantly reduced the sensitivity
of the enzyme toward GTG.7 Recently, we have shown
that trialkyl/aryl gold(I) chlorides (R3PAuCl, R = Me,
Et or Ph) inhibit the GPx activity of the selenol 5 by
forming gold(I)-selenolate complexes (6–8). 8 Gimeno
and co-workers reported similar gold–selenolates
(9–10) bearing the N,N-dimethylbenzylamine moiety
(figure 2).9
It has been reported that the amino group in 5 plays
an important role in the GPx activity as the Se· · · N
non-covalent interactions in the key catalytic interme-
diates modulate the catalytic activity.8,10 In the natu-
ral GPx enzyme, two amino acid residues, glutamine
(Gln) and tryptophan (Trp), form a ‘catalytic triad’ with
the Sec residue at the active site.11 In ID-1 and TrxR,
histidine residues (His) have been shown to play cruc-
ial roles in the catalysis.12 However, it is not known
whether these proximal amino acid residues modu-
late the reactivity or stability of the gold–selenolate
complexes during inhibition by gold(I) complexes. In
this paper, we describe, for the first time, the mode
of ligand exchange reactions at Au(I) center in gold–
selenolates in the presence or absence of any Se· · · N
interactions.
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Figure 1. Chemical structures of therapeutic gold(I)
compounds 1–4.
2. Experimental
2.1 General procedure
Trimethylphosphine gold(I) chloride, triethylphosphine
gold(I) chloride, triphenylphosphine gold(I) chloride
and sodium borohydride were purchased from Sigma-
Aldrich. The experiments were carried out under dry
and oxygen-free nitrogen using standard Schlenk tech-
niques for the synthesis. 1H (400 MHz), 13C (100 MHz),
31P (162 MHz) and 77Se (76 MHz) NMR spectra were
obtained on a Bruker 400 MHz NMR spectrometer.
Chemical shifts are cited with respect to Me4Si as inter-
nal (1H and 13C), H3PO4 (31P) and Me2Se as exter-
nal (77Se) standards. Mass spectral studies were carri-
ed out on a Bruker Daltonics Esquire 6000plus mass
spectrometer with ESI-MS mode analysis. The di-
selenide 11 was synthesized following the literature
method.13a
2.2 Synthesis of gold–selenolates 13–15
To a deoxygenated aqueous solution of the disele-
nide 11 (30.0 mg, 0.094 mmol) was added sodium
borohydride (35.0 mg, 0.940 mmol) to generate the
corresponding selenol 12. The resulting selenol was
extracted with deoxygenated chloroform and then the
appropriate phosphine gold(I) chloride (0.094 mmol)
was added. The reaction mixture was stirred at room
temperature for 1 h. The solvent was evaporated
in vacuo. The gold(I) selenolates 13–15 were obtained
as yellow semi-solid products in almost quantitative
yields.
2.2a Compound 13: 1H NMR (CDCl3) δ (ppm):
1.66–1.69 (d, J = 12.0 Hz, 9H), 3.63 (s, 3H), 6.94
(s, 1H), 7.09 (s, 1H). 13C NMR (CDCl3) δ (ppm): 14.9
(d, JC-P = 37.0 Hz), 35.1, 118.1, 121.0, 139.9. 31P NMR
(CDCl3) δ (ppm): −0.6. 77Se NMR (CDCl3) δ (ppm):
34. ESI-MS m/z calcd. for C7H14N2AuPSe [M+H]+
434.9; found 434.8.
2.2b Compound 14: 1H NMR (CDCl3) δ (ppm):
1.10–1.19 (m, 9H), 1.91 (m, 6H), 3.64 (s, 3H),
6.97 (d, J = 2.0 Hz, 1H), 7.09 (d, J = 2.0 Hz,
1H). 13C NMR (CDCl3) δ (ppm): 9.4, 17.9 (d, JC-P =
34.0 Hz), 36.6, 119.7, 122.5, 141.0. 31P NMR (CDCl3)
δ (ppm): 36.1.77Se NMR (CDCl3) δ (ppm): 46. ESI-MS
m/z calcd. for C10H20N2AuPSe [M+H]+ 477.0; found
477.0.
2.2c Compound 15: 1H NMR (CDCl3) δ (ppm):
3.68 (s, 3H), 6.88 (s, 1H), 7.10 (s, 1H), 7.42–7.49
(m, 10H), 7.57–7.63 (m, 5H). 13C NMR (CDCl3) δ
(ppm): 36.6, 119.5, 121.9, 129.5 (d, JC-P = 11.0 Hz),
130.0, 130.7, 131.9, 134.7 (d, JC-P = 13.0 Hz),
143.7, 143.9. 31P NMR (CDCl3) δ (ppm): 35.6. 77Se
NMR (CDCl3) δ (ppm): 22. ESI-MS m/z calcd. for
C22H20N2AuPSe [M+H]+ 621.0; found 620.9.
Figure 2. Chemical structures of selenol 5 and gold(I)–selenolate complexes 6–10.
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2.3 General procedure for the reaction of gold–
selenolates with selenolate and phosphines
The reactions of gold–selenolates 13–15 with seleno-
late 12 and triphenylphosphine (PPh3) were carried out
in NMR tube using MeOH as solvent. To a methano-
lic solution of complexes 13–15, was added required
amount of either selenolate 12 (freshly prepared by the
reduction of the corresponding diselenide 11) or PPh3.
The resultant solution was mixed thoroughly and then
studied by 77Se, 31P NMR and ESI-MS techniques to
understand the ligand exchange reactions and to analyse
the final products.
2.4 X-ray crystallography
Single crystal X-ray diffraction data was collected on
a Bruker AXS SMART APEX CCD diffractometer at
room temperature (291 K). The X-ray generator was
operated at 50 KV and 35 mA using Mo–Kα radia-
tion (λ = 0.71073 Å). The data was collected using
SMART software package.14 The data were reduced by
SAINTPLUS,14 an empirical absorption correction was
applied using the package SADABS15 and XPREP14
was used to determine the space group. The crystal
structure was solved by direct methods using SIR9216
and refined by full-matrix least-squares method using
SHELXL97.17 All non-hydrogen atoms were refined
anisotropically and hydrogen atoms were assigned at
idealized locations.
2.4a Crystal data for compound 13:18 C7H15N2PSeAuCl;
Mr = 469.5; monoclinic; space group: P21/c; a =
11.8096(28) Å; b = 26.4283(61) Å; c = 11.5510(27)
Å; α = 90.00(0)o; β = 113.270(4)o; γ = 90.000(0)o;
V = 3311.89(63) Å3; ρcalc = 1.88 g m−3; Z = 8;
MoKα radiation (λ = 0.71370 Å); T = 291(2) K; Rint:
0.054; R (observed data): R1 = 0.061; wR2 = 0.105;
R (all data): R1 = 0.043; wR2 = 0.099; GOF = 0.929;
ρmin and ρmax (eÅ−3): −1.733 and 2.010.
3. Results and discussion
3.1 Synthesis of gold(I)–selenolates
The imidazole-based gold–selenolates 13–15 were syn-
thesized by treating R3PAuCl (R = Me, Et or Ph) with
the selenolate 12 (scheme 1). The diselenide 11 can
be quantitatively reduced to the corresponding selenol
12 by the treatment of NaBH4.13 The selenol produced
in this reaction exists predominantly in its zwitterionic
form (2B) having a large negative charge on selenium
atom as shown in scheme 1. A nucleophilic attack of the
selenol 12 at the Au(I) centre of R3PAuCl produces the
corresponding gold–selenolates 13–15 almost in quanti-
tative yields. All the gold–selenolates were characteriz-
ed by NMR (1H, 13C, 31P and 77Se) spectroscopic and
ESI-MS spectrometric techniques.
3.2 Structural features of gold(I)–selenolate 13
To understand the important structural features in the
gold–selenolates, complex 13 was studied by single
crystal X-ray diffraction. After the synthesis of complex
13 in chloroform, the crude compound was recrystal-
lized from chloroform/methanol (1:1) mixture to afford
faint yellowish needle-shaped crystals. As shown in
figure 3, the structure of complex 13 was found to be
dimeric with a weak Au· · · Au non-covalent aurophilic
interaction (dAu1· · · Au2 = 3.104 Å), which was much
shorter than the sum of van der Waals radii of Au atoms
(3.40 Å).
As expected, an almost linear arrangement of Se–
Au–P moieties were observed (θSe1-Au1-P1: 175.9o
and θSe2-Au2-P2: 172.4o), which is a characteristic
of Au(I) complexes.4,9 A small deviation from the lin-
earity is probably due to the presence of Au· · · Au
aurophilic interaction. Similar structural features were
also observed for complexes 9 and 10 as reported by
Gimeno and co-workers.9 While the Au· · · Au distance
of 3.104 Å in complex 13 is comparable to that of 9
(3.091 Å), the distance is found to be slightly longer
Scheme 1. Synthetic routes to the gold–selenolates (13–15). (i) NaBH4, CHCl3/
H2O; (ii) R3PAuCl (R = Me, Et or Ph), CHCl3.
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Figure 3. X-ray crystal structure of gold–selenolate comp-
lex 13. Displacement ellipsoids are drawn at 50% probability
level and hydrogen atoms are shown as small spheres of arbi-
trary radii. Two chloride counterions (Cl−) in the molecule
are omitted for the structural clarity.
than that reported for complex 10 (3.024 Å). Although
two Cl− counterions were present in the crystal struc-
ture of complex 13, both of the Cl− ions were far away
from the Au and Se centres. Furthermore, both the
Cl− ions were located nearer to one imidazole-gold-
selenolate unit. For example, the distance of Cl− ions
from Au2 and Se2 are found to be much higher than
the distance from Au1 and Se1 centres. However, all
these distances are much higher than the sum of van der
Waals distance of Se/Au and Cl atoms indicating the
absence of any non-bonded interactions (table 1).
3.3 Ligand exchange reactions in gold(I)-selenolates
It has been shown that ligand exchange reactions play
an important role in the inhibition of GPx.5 For exam-
ple, GTG undergoes ligand displacement reactions with
glutathione (GSH) to produce [Au(SG)2]− complex,
which is probably responsible for the inhibition of
the enzyme.5c The synthetic gold–selenolate complexes
6–8 also undergo extensive ligand exchange reactions
in the presence of selenol 5 and phosphines.8 In these
reactions, the trialkyl/aryl phosphines were eliminated,
which underwent further reactions with oxygen and
selenium powder to produce the corresponding phos-
phine oxides (R3P=O) and selenides (R3P=Se).8 In con-
trast, reactions of the imidazole-based selenol 12 with
trialkyl/aryl gold chlorides produced the corresponding
gold–selenolates (13–15) and the formation of phos-
phine oxides or selenides was not observed. These
observations indicate that the Se· · · N interactions in
complexes 6–8 may activate the S–Au and Au–P bonds
toward ligand displacement reactions. When complex 6
was treated with 5, the formation of bis-selenolate–gold
complex 16 was observed due to the replacement of the
phosphine ligand by the selenol (scheme 2).8 In con-
trast, no such reaction was observed when complex 14
was treated with an equimolar amount of compound 12.
Although a small amount of triethyl phosphine oxide
(Et3P=O) was observed in the reaction, the ESI-MS
spectrum indicated that the selenolate and phosphine
ligands are intact in complex 14 (figures S13 and S14 of
Supporting Information). These observations indicate
that the notable differences in reactivity of complexes
6–8 and 14 towards corresponding selenols are proba-
bly due to the differences in nucleophilicity/basicity of
–NMe2 and Cl− moieties.
A striking difference in the reactivity of these two
types of gold–selenolates toward selenols prompted us
to investigate the phosphine exchange reactions. As
Table 1. Some important bond distances, bond angles and non-bonding distances
in the crystal structure of complex 13.
Au1–Se1 2.440(1) Au2–Au1–Se1 83.33(3) Au1· · ··Au2 3.104
Au1–P1 2.267(2) Au2–Au1–P1 102.72(6) Se1· · ··Cl1 4.926
Au2–Se2 2.4396(9) Se1–Au1–P1 172.41(7) Se1· · ··Cl2 8.988
Au2–P2 2.266(2) Au1–Au2–Se2 86.89(2) Au1· · ··Cl1 3.947
Se2–C8 1.882(9) Au1–Au2–P2 96.97(6) Au1· · ··Cl2 6.620
Se1–C1 1.89(1) Se2–Au2–P2 175.98(7) P1· · ··Cl1 4.002
P1–C6 1.79(1) Au2–Se2–C8 101.1(3) P1· · ··Cl2 4.441
P1–C5 1.80(1) Au1–Se1–C1 96.8(3) Se1· · ··Au2 3.719
P1–C7 1.79(1) Au1–P1–C6 110.5(4) Se2· · ··Au1 3.842
P2–C13 1.83(1) Au1–P1–C5 112.8(4) N1H1· · ··Cl1 2.298
P2–C12 1.82(1) Au1–P1–C7 116.5(4) N1· · ··Cl1 3.109
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Scheme 2. Nucleophilic attack of the selenol 5 at the
Au(I)-centre in gold–selenolates 6–8 produces the bis-
selenolate-gold complex 16. No such reaction was observed
when the selenolate 12 was added to complex 14.
shown previously, addition of PPh3 to the benzylamine-
based gold–selenolate complexes 6–7 leads to a rapid
elimination of PMe3 or PEt3 to produce complex 8. 8
In contrast, the imidazole-based gold–selenolates
13–14 do not undergo any phosphine displacement
reactions in the presence of PPh3. For example, the
treatment of 14 with an excess amount (∼5 equiv) of
PPh3 does not produce the phosphine-exchanged pro-
duct 15. Interestingly, the 31P NMR spectroscopic and
ESI-MS spectrometric analyses revealed the formation
of [Et3PAuPPh3]+ species, indicating that the addition
of PPh3 led to the elimination of the selenolate li-
gand. The [Et3PAuPPh3]+ species produced in the reac-
tion reacts with PPh3 to produce [(PPh3)2Au]+ cation
by phosphine exchange reactions (scheme 3). Further-
more, the produced cationic gold–phosphine complexes
such as [Et3PAuPPh3]+ and [(PPh3)2Au]+ may undergo
a charge balance with Cl− counterions as shown in
scheme 3. As expected, a line broadening in 31P NMR
signal was observed during the course of phosphine
exchange reactions. Although there is no direct evi-
dence, the elimination of selenolate in the reaction of 14
with PPh3 is probably due to the stronger trans effect of
the phosphine ligand as compared to the selenolate li-
gand, which leads to the weakening of the Au–Se bond.
Whereas, the Se· · · N interactions in the benzylamine-
based gold–selenolates 6–8 may reduce the trans direct-
ing effect of phosphine group, leading to the weaken-
ing of the Au–P bonds. This may facilitate the
phosphine exchange reactions as shown in scheme 3.
These observations lead to the assumption that the non-
bonded interactions at the selenium centres in gold–
selenolates may modulate the ligand exchange reactions
at the Au(I) centres.
N
Se Au PR3
6, R = Me; 7, R = Et
N
H
N
Se [Et3PAuPPh3]
12
PPh3-PEt3
N
H
N
Se Au PEt3
14
PPh3
N
Se Au PPh3
PPh3
(5 equiv)
8
[Ph3PAuPPh3]
(5 equiv)
-PR3
Cl
Cl
Cl
Scheme 3. Differences in the reactivity of complexes 6,
7 and 14 towards PPh3.
3.4 Possible pathways of different ligand exchange
reactions
Coffer et al. have previously shown that the nucleo-
philic attack of the Cys-34 residue of albumin at the
Au(I) centre of AUR leads to the formation of protein–
gold–phosphine (Alb–S–AuPEt3) complex, indicating
that the replacement of thioglucose moiety is more
favoured than that of the PEt3 ligand.3a However, it is
not clear whether the elimination of gold(I)–phosphine
moiety from an enzyme active site alters the inhibi-
tion property of the gold(I) complexes. The present
study indicates that the nature of selenolate can alter
the ligand exchange reactions at the gold(I) centre. This
study also suggests that the effect of gold(I) drugs on
selenoenzymes not only depends on the reactivity of
Sec toward these gold(I) complexes, but also the sta-
bility of Se–Au bond in the enzyme-bound complex.
For example, the presence of a ligand (L) in biologi-
cal medium may have different effects on the gold(I)–
selenocysteine complexes as shown in scheme 4. In the
first scenario, the addition of L does not lead to any li-
gand displacement reactions. In such case, the enzyme
activity is expected to be strongly inhibited by the treat-
ment of enzyme with gold(I) complexes such as AUR.
In the second pathway, the replacement of phosphine
ligand by L may not affect the inhibition as the Sec
residue is still bonded to the gold(I) moiety. In contrast,
a recovery of enzyme activity is expected when the lig-
and L attacks at the Au(I) centre to release the cata-
lytically active selenol (scheme 4). Therefore, the li-
gand exchange reactions at the Au(I) centres in protein–
gold complexes may or may not affect the inhibition
of enzymatic activity depending on the relative strength
of protein(Sec)–gold and gold–phosphine bonds. Fur-
thermore, this scheme indicates that, for an effective
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Scheme 4. Schematic representation of different ligand exchange reaction
pathways in gold(I)–selenocysteine complexes in enzymes.
inhibition of selenoenzymes by gold(I) drugs, the Se–
Au bond should be more stable than that of the Au–P
bonds.
4. Conclusion
In summary, some imidazole-based gold(I)–selenolates
have been synthesized, characterized and studied for
their reactivity towards different nucleophiles. This
study indicates that the nature of selenolate plays
an important role in ligand exchange reactions in
gold–selenolates. The reactivity of the imidazole-
based gold(I)–selenolates toward selenols and phos-
phines is significantly different from that of the N,N-
dimethylbenzylamine-based gold(I) complexes. The
strong trans effect of phosphines probably makes the
Au(I)–Se bond relatively weaker, leading to the cleav-
age of Au(I)–Se bond in gold(I)–selenolates upon the
nucleophilic attack of selenols and phosphines. These
observations suggest that the effect of gold(I) drugs on
selenoenzymes may not only depend on the reactivity of
Sec toward these gold(I) complexes, but also on the sta-
bility of Se–Au bond in the gold(I)–selenolate complex
of the enzyme.
Supporting information
NMR and ESI-MS spectral data of all the gold–
selenolate complexes are given in supplementary
information (figures S1–S18). Supplementary data to
this article can be found in the Website www.ias.ac.
in/chemsci.
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